{"public_id":"cl_2017a7ba0d0509b9c61c33ae5603498c","status":"active","superseded_by_public_id":null,"corpus_id":205099724,"text":"Thrombocytopenia, rash, and peripheral neuropathy occurred more frequently in the ixazomib group than in the placebo group (grade 3/4 thrombocytopenia, 12%/7% vs. 5%/4%; rash, 36% vs. 23%; peripheral neuropathy, 27% vs. 22%).","confidence":0.9,"paper":{"corpus_id":205099724,"title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","url":"https://sah.borca.ai/papers/205099724"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_174c51fbb203a98e09edf479567bf84c","name":"peripheral neuropathy","description":"Nerve damage causing numbness or pain in the extremities, monitored as an adverse event given the proteasome inhibitor drug class.","types":["adverse event"],"url":"https://sah.borca.ai/concepts/co_174c51fbb203a98e09edf479567bf84c"},{"public_id":"co_60db04bb45645e50c064ded2b8cb25be","name":"rash","description":"A skin adverse event reported more frequently in patients receiving ixazomib.","types":["adverse event"],"url":"https://sah.borca.ai/concepts/co_60db04bb45645e50c064ded2b8cb25be"},{"public_id":"co_bf5fec270b8d3a2a756035c512870721","name":"thrombocytopenia","description":"A reduction in blood platelet count reported as an adverse event in this trial.","types":["adverse event"],"url":"https://sah.borca.ai/concepts/co_bf5fec270b8d3a2a756035c512870721"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_2017a7ba0d0509b9c61c33ae5603498c"}